MedTrace Logo

A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF)

NCT06343727 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-04-22

No results posted yet for this study

Summary

The goal of this clinical trial is to compare protein supplements in patients with kidney failure on dialysis. The main questions it aims to answer are:

* To determine whether the supplementation of egg white protein pudding in a population of individuals with kidney failure on dialysis is feasible.
* To determine whether egg white protein pudding supplementation improves serum albumin similar to other standard nutritional supplements.
* To determine the effects of the egg white protein pudding on frailty measures, dietary intakes and analytes in the blood. Participants will receive either the egg white pudding (experimental) or control (Ensure plus) at the end of their dialysis treatments 3-days per week for 12 weeks.

Conditions

Interventions

DIETARY_SUPPLEMENT

Egg white protein pudding

Will consume one egg white protein pudding at the end of their dialysis treatments 3-days per week for 12 weeks

DIETARY_SUPPLEMENT

: Ensure Plus

Will consume one Ensure Plus at the end of their dialysis treatments 3-days per week for 12 weeks

Sponsors & Collaborators

  • University of Manitoba

    collaborator OTHER

  • Manitoba Egg Farmers

    collaborator UNKNOWN

  • Seven Oaks Hospital Chronic Disease Innovation Centre

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-25
Primary Completion
2026-08-11
Completion
2026-10-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06343727 on ClinicalTrials.gov